Strategic Advancements and Promising Outlook Drive Zevra Therapeutics’ Growth Prospects
William Blair analyst Sami Corwin has maintained their bullish stance on ZVRA stock, giving a Buy rating today. Sami Corwin’s rating is ...
CAMP4 Analyst Highlights Rare Disease Platform Potential
CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...
Camp4 Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $17 price target The firm believes CMP-CPS-001, the lead ...
Forbes23d
Bitcoin May Shift To A Super Cycle, Breaking The Crypto Market Norm
The cryptocurrency world is witnessing a seismic shift as bitcoin, the pioneer in digital assets, appears to be breaking free from its long-established four-year cycle in favor of a so-called ...
The Daily Pennsylvanian29d
Penn Med, Children’s Hospital of Philadelphia receive $14 million grant for gene-editing research
Researchers will aim to target developing therapies for urea cycle disorders, which affect approximately one in every 35,000 children, according to the Penn Medicine announcement. Central to the ...